US-based device manufacturer Reprieve Cardiovascular has secured $42m in funding for its heart failure tech trials.
The capital will be directed towards the development of the company’s automated diuretic and fluid management devices, which are designed to remove the fluid in the cardiovascular systems of people suffering from heart failure.
At the same time, the company has said that the funding will also be used to help accelerate the implementation of the Fluid management of the Acute decompensated heart failure Subjects Treated with Reprieve system (FASTR) Trial (NCT05174312 ), as well as a newly announced upcoming pivotal trial.
Reprieve has said that its primary offering, the Reprieve System, monitors physiological parameters such as urine output, to deliver patient-specific diuretic dosing and fluid replacement for patients living with acute decompensated heart failure (ADHF).
The FASTR Trial pilot study aims to determine if decongestive therapy administered by the Reprieve system can more efficiently decongest ADHF when compared to traditional methods. The trial is set to take place across the US and UK and aims to enrol an estimated 100 participants.
A previous trial carried out by Reprieve Cardiovascular in 2019 was a first-in-human clinical trial of its fully automated fluid management system dubbed the Personalized Volume Management System, which found it could produce effective and long-lasting decongestion in patients suffering from ADHF.
Reprieve Cardiovascular CEO Mark Pacyna said: “Today, the standard of care for heart failure patient fluid removal is diuretics. Originally approved 60 years ago, diuretics remain the primary treatment option but can be difficult to administer optimally without real-time patient information.
“Reprieve Cardiovascular is bringing intelligent decongestion management to heart failure patients. The Reprieve system provides physicians and care teams added visibility and control throughout treatment.”
The round of funding was co-launched by venture capital companies Lightstone Ventures and Sante Ventures, joined by Deerfield Management, Genesis Capital, and Arboretum Ventures.
Elsewhere in the indication of ADHF, Cardionomic has completed patient enrolment for two upcoming pilot studies, STIM-ADHF and STOP-ADHF, designed to examine its pulmonary nerve stimulation system as a treatment for the condition.
Canary Medical has also completed the first-in-human clinical trial of its Cardiac Auscultation monitoring sensor device implantable sensor is aimed at enhancing the management of congestive heart failure symptoms.
GlobalData’s Medical Device Intelligence Centre estimates that the US-based heart failure market is set to be worth $70bn by 2030.
